Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
Locations - Netherlands - Study Site Leiden -

Leids Universitair Medisch Centrum

paragraph image
Albinusdreef 2
2333 ZA Leiden

Outpatient clinic Neurology - J3-Q

Prof. Dr. R.A.C. Roos: monday, all day.
Consultation only with appointment and referrel letter.
Tel: 071-526 2111

Huntington spreekuur

paragraph image
Spreekuur op afspraak met verwijsbrief bij Prof. Dr. R.A.C. Roos: maandag, gehele dag. 
Polikliniek Neurologie - J3-Q 
Tel: 071-526 2111
Klik op de plattegrond hier naast voor een overzicht van de zones binnen het LUMC.

Over ons

Het multidisciplinaire Huntington team van het Leids Universitair Medisch Centrum verzorgt jaarlijks de zorgverlening voor meer dan 300 patiënten met de ziekte van Huntington, gendragers en risicodragers. Daarnaast wordt er veel wetenschappelijk onderzoek uitgevoerd, waarbij de afdelingen neurologie, psychiatrie, klinische genetica, humane genetica, radiologie en endocrinologie samenwerken. Tevens is er een directe samenwerking met het verpleeghuis Overduin (Topaz) te Katwijk, waar meerdere afdelingen gespecialiseerde zorg voor patiënten met de ziekte van Huntington bieden. Ook is hier dagbehandeling met o.a. logopedie, fysiotherapie en ergotherapie mogelijk. 

Contactpersonen wetenschappelijk onderzoek


Public transport

Leiden University Medical Center is located, within walking distance, next to Leiden Central Station. Several buses stop outside the LUMC stop called Bargelaan at the back of the station. All buses stop at the bus station in front of the station. 


Current ongoing research projects:

The Leiden Huntington Study Group has a broad interest and activity in HD research. Examples of ongoing research are:

- Enroll-HD: a worldwide, observational study for persons with Huntington's Disease (HD) and their families to collect data to improve our understanding and treatment of HD. 

- PRIDE-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease.

- research on the progression of cognitive abilities and psychiatric problems over the years in Huntington’s disease.

- research to identify connections between different brain areas on MRI scans, and so analyse the differences and developments in these areas between people with Huntington’s disease (in an early stage and without symptoms) compared to healthy controls over a period of three years.

- research using MRI as well as electrophysiological techniques, this study is aimed at assessing both structure and function of the brain in Huntington’s disease and measuring rates of change over time compared to that of people not carrying the mutated gene. This type of “biomarker” research is important for understanding and measuring disease progression, which in turn can be used to better understand the effect of potential therapies  

- research at the department of Human Genetics focusses on finding the molecular mechanisms behind the disease and use this knowledge to develop novel therapies. Also finding good biomarkers that can track the progression of the disease in blood samples from Huntington disease patients is an important research line. These biomarkers are vital for future clinical trial to measure if a new treatment is effective.